Sort by
Refine Your Search
-
Listed
-
Employer
- Ghent University
- VIB
- Université catholique de Louvain
- Nature Careers
- KU LEUVEN
- University of Antwerp
- IMEC
- Université libre de Bruxelles (ULB)
- Flanders Institute for Biotechnology
- Vrije Universiteit Brussel
- KU Leuven
- Royal Military Academy
- Vrije Universiteit Brussel (VUB)
- Washington State University
- altertox
- 5 more »
- « less
-
Field
-
the development of strategic workforce planning, serving as the vital link between financial insights and HR strategies. You’ll translate data and plans into concrete strategic actions that help secure
-
services of the department WHAT WE ARE LOOKING FOR You hold a degree of Master in Drug Development, Master in Pharmaceutical Sciences (with a clear focus on drug development), Master of Biomedical Sciences
-
Job description You will be responsible for advancing the current state of metaproteomics bioinformatics by developing novel, high-performance algorithms for improved identification and annotation
-
to aid in the execution of laboratory research and management of lab resources. The lab works on genomics, cell biology, diagnostics and vaccine development for Anaplsma spp. Work will include but is
-
the Joint Research Centre of the European Commission will focus on further development of innovative health biotechnological drugs, more specifically mRNA therapeutics. As the science and knowledge service
-
to the development of obesity, diabetes and liver cancer, and to explore novel approaches for combating the pathologies. The Signal Transduction & Metabolism Laboratory provides a world leading environment for
-
launching new spin-offs, licensing intellectual property to companies, engaging in dynamic partnerships and fostering talent development. VIB has created >40 spin-offs such as Confo Therapeutics, Augustine Tx
-
. The mission is (but not limited) to: Lead an international research group in Computer Vision, sustained by competitive research and innovation funding Lead and develop excellent research and technology transfer
-
. These will be targeted with gene therapeutic agents (GTAs) delivered during EVLP to selectively modulate immune responses and improve long-term outcomes. The DC1 objectives are: To develop a mouse model
-
of industrial machinery. The challenge is to reduce the radiated noise, without adding too much weight, while accounting for the fact that operational speeds might vary. The objective of this DC is to develop a